series-a
Stage
2007
Founded
2
Investors
About
Xintela is a clinical-stage biopharma company developing stem cell therapies for conditions like osteoarthritis and cancer treatments targeting aggressive tumors. Its proprietary technology uses the stem cell marker integrin α10β1 to select and quality-assure stem cells in the product XSTEM®.
Explore Xintela's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.